T0318

Tranilast

≥98% (HPLC), LTC4 inhibitor, powder

• Sinonimo/i: 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid, 3,4-DAA, N-(3,4-Dimethoxycinnamoyl)anthranilic acid, Rizaben, SB-252218
• Formula empirica (notazione di Hill): C₁₈H₁₇NO₅
• Numero CAS: 53902-12-8
• Peso molecolare: 327.33
• UNSPSC Code: 41106500
• PubChem Substance ID: 24278719
• NACRES: NA.77
• MDL number: MFCD00864787
• Assay: ≥98% (HPLC)
• Form: powder

Proprietà

• Nome del prodotto: Tranilast, ≥98% (HPLC), powder
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• mp: 166.2-168.2 °C (lit.)
• solubility: DMSO: >10 mg/mL, H₂O: insoluble
• originator: Kissei
• storage temp.: 2-8°C
• SMILES string: COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC
• InChI: 1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
• InChI key: NZHGWWWHIYHZNX-CSKARUKUSA-N
• Gene Information: human ... VEGFA(7422), VEGFB(7423), VEGFC(7424)

Descrizione

Application

The effect of Tranilast on mast cell surface receptors was studied in murine bone marrow-derived mast cells.

Biochem/physiol Actions

Tranilast is an anti-asthma drug, which inhibits LTC₄ and PGE₂ formation in stimulated monocytes, but does not inhibit cyclooxygenase or lipoxygenase activity; inhibits mast cell degranulation; inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro. Tranilast may represent a new class of drugs for therapy to treat ongoing T_H1-mediated autoimmune diseases.

Tranilast is an anti-asthma drug, which inhibits LTC₄ and PGE₂ formation in stimulated monocytes, inhibits mast cell degranulation, and inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro.

Tranilast also inhibits vascular smooth muscle cell proliferation by inhibiting the cyclin-dependent kinase inhibitor-1(p21Waf1/Cip1) and may be useful in treating cardiac allograft vasculopathy. It is used in treating hypertrophic scars and keloids. Tranilast inhibits tumor necrosis factor (TNF-α and TGF-β2), obstructing epithelial-mesenchymal transition in human retinal pigment epithelial cell line (ARPE).

Features and Benefits

This compound was developed by Kissei. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informazioni sulla sicurezza

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Classe di stoccaggio: 11 - Combustible Solids
• wgk: WGK 3
• ppe: dust mask type N95 (US), Eyeshields, Gloves